TRAW Traws Pharma, Inc.
Price Chart
Executive Summary
Traws Pharma announced a new broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks, utilizing a proprietary dual-strike mechanism. The company is advancing non-clinical development and scaling manufacturing, with planned interactions with the CDC, NAFDAC, and AMA. No financial data, clinical data, or regulatory milestones were disclosed.
Actionable Insight
This is an early-stage pipeline announcement with no clinical data or regulatory milestones. Monitor for future non-clinical or clinical data readouts and any government stockpiling contracts. The stock may see speculative interest given the outbreak context, but fundamental catalysts remain distant.
Key Facts
- Announced antiviral program targeting Hantavirus and Ebola Virus Disease outbreaks
- Novel dual-strike mechanism combining host nucleotide depletion and forced lethal incorporation
- Both components of the combination have been safely evaluated in human studies as single agents
- Advancing non-clinical development in BSL-3 and BSL-4 animal models
- Scaling chemical development and manufacturing for potential stockpiling
- Planned interactions with CDC; ongoing with NAFDAC and AMA
- No clinical data, financial figures, or regulatory milestones provided
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- Pre-clinical stage — no guarantee of successful clinical translation
- No disclosed funding or budget for the program
- FDA clinical hold on lead program tivoxavir marboxil noted in forward-looking statements
- Regulatory pathways for Hantavirus/Ebola are complex and may require animal rule or emergency use authorization
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-066623 |
| Document: tm2615712d1_ex99-1.htm | 0001104659-26-066623 |
| Document: 0001104659-26-066623-index-headers.html | 0001104659-26-066623 |
| Document: 0001104659-26-066623-index.html | 0001104659-26-066623 |
| Document: 0001104659-26-066623.txt | 0001104659-26-066623 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
8-K
| $1.29 awaiting T+5 | awaiting T+5 | — | $1.28 (+0.78%) |
|
May 29, 2026
15d ago
|
DEFA14A
| $1.46 $1.45 | ▼ −0.68% | ▼ −0.39% | $1.28 (−12.33%) |
|
May 27, 2026
17d ago
|
8-K
| $1.53 $1.42 | ▼ −7.19% | ▼ −8.40% | $1.28 (−16.34%) |
|
May 26, 2026
17d ago
|
8-K
| $1.53 $1.45 | ▼ −5.23% | ▼ −5.70% | $1.28 (−16.34%) |
|
May 22, 2026
22d ago
|
424B5
| $1.49 $1.47 | ▲ +1.34% | ▲ +3.02% | $1.28 (+14.09%) |
|
May 18, 2026
26d ago
|
EFFECT
| $1.76 $1.58 | ▲ +10.23% | ▲ +11.85% | $1.28 (+27.27%) |
|
May 15, 2026
29d ago
|
8-K
| $1.88 $1.49 | ▲ +20.74% | ▲ +21.71% | $1.28 (+31.91%) |
|
May 15, 2026
29d ago
|
Press Release
| $1.88 $1.49 | ▼ −20.74% | ▼ −21.71% | $1.28 (−31.91%) |
|
May 8, 2026
5w ago
|
S-3
| $2.02 $1.76 | ▲ +12.87% | ▲ +12.79% | $1.28 (+36.63%) |
|
May 8, 2026
5w ago
|
Press Release
| $2.18 $1.63 | ▼ −25.23% | ▼ −26.69% | $1.28 (−41.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access